TABLE 3.
NTRK Testing
| Variable | Non-TRKi (n = 27) | TRKi (n = 28) | All (N = 55) |
|---|---|---|---|
| NTRK test type, n (%) | |||
| NGS | 27 (100) | 27 (96) | 54 (98) |
| Caris Life Science | 0 (0) | 7 (26) | 7 (13) |
| MI Tumor Profile | 0 (0) | 4 (67) | 4 (67) |
| MI Intelligence Profile | 0 (0) | 1 (17) | 1 (17) |
| Unknown | 0 (0) | 1 (17) | 1 (17) |
| Foundation Medicine | 13 (48) | 5 (19) | 18 (33) |
| FoundationOne CDx | 8 (62) | 6 (86) | 14 (70) |
| FoundationOne Heme | 3 (23) | 1 (14) | 4 (20) |
| FoundationOne NOS | 2 (15) | 0 (0) | 2 (10) |
| NeoGenomics Laboratories | 1 (4) | 1 (4) | 2 (4) |
| Tempus | 7 (26) | 6 (22) | 13 (24) |
| Xt Targeted Panel | 6 (86) | 6 (86) | 12 (86) |
| Tempus xF | 1 (14) | 1 (100) | 2 (100) |
| Other | 6 (22) | 7 (26) | 13 (24) |
| RT-PCR | 0 (0) | 1 (4) | 1 (2) |
| FISH | 0 (0) | 2 (7) | 2 (4) |
| NTRK fusion type, n (%)a | |||
| NTRK1 | 14 (52) | 11 (39) | 25 (45) |
| NTRK2 | 5 (19) | 3 (11) | 8 (15) |
| NTRK3 | 9 (33) | 13 (46) | 22 (40) |
| NTRK1 fusion gene partner, n (%) | |||
| TPM3 | 5 (36) | 2 (20) | 7 (29) |
| LMNA | 4 (29) | 0 (0) | 4 (17) |
| TPR | 0 (0) | 2 (20) | 2 (8) |
| TP53 | 1 (7) | 0 (0) | 1 (4) |
| Other | 3 (21) | 4 (40) | 7 (29) |
| Unknown | 1 (7) | 2 (20) | 3 (12) |
| NTRK2 fusion gene partner, n (%) | |||
| KCTD16 | 1 (20) | 1 (33) | 2 (25) |
| Other | 3 (60) | 2 (67) | 5 (62) |
| Unknown | 1 (20) | 0 (0) | 1 (12) |
| NTRK3 fusion gene partner, n (%) | |||
| ETV6 | 8 (89) | 6 (46) | 14 (64) |
| EML4 | 0 (0) | 3 (23) | 3 (14) |
| EML3 | 0 (0) | 1 (8) | 1 (5) |
| Other | 1 (11) | 2 (15) | 3 (14) |
| Unknown | 0 (0) | 1 (8) | 1 (5) |
FISH = fluorescence in situ hybridization; NGS = next-generation sequencing; NTRK = neurotrophic tyrosine receptor kinase; RT-PCR = reverse transcription polymerase chain reaction; TRKi = tyrosine receptor kinase inhibitor.